Iovance Biotherapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $99.3 million, a 66% increase year-over-year and a 39% increase sequentially from Q1 2026.

Amtagvi Revenue: Approximately $91 million, exceeding guidance of $79 million to $81 million, and up 51% from Q1 2026.

Proleukin Revenue: About $9 million, down from $11 million in Q1 due to inventory timing.

Gross Margin: Reached an all-time high of 56%, up from 41% in Q1 2026, driven by higher sales volume and operational efficiencies.

R&D Expenses: Approximately $59 million, down from $62 million in Q1, marking the fourth consecutive quarter of cost savings.

Cash Position: Approximately $304 million as of June 30, 2026, expected to fund operations into the second half of 2028.

2Strategic Updates and Business Highlights

Commercial Launch: Strong momentum with more than 50 patients per month receiving Amtagvi, reflecting increased manufacturing scale and accessibility.

Regulatory Milestones: Fast Track designation granted for SAR-201 in advanced soft tissue sarcomas; nearing completion of enrollment in pivotal LUN-202 trial for non-squamous, non-small cell lung cancer.

Clinical Advancements: Positive early Phase 2 data for TIL therapy in metastatic serous endometrial cancer, with a 40% confirmed objective response rate.

ATC Network Expansion: Increased number of authorized treatment centers (ATCs) to over 95, with a goal of reaching at least 110 by year-end.

3Forward Guidance and Outlook

Revenue Guidance: Reviewing full-year 2026 guidance of $350 million to $370 million, with an update expected in Q3 based on strong Q2 performance.

Demand Expectations: Anticipated continued growth in demand for Amtagvi in Q3 and Q4, supported by rising physician awareness and expanding ATC network.

4Bad News, Challenges, or Points of Concern

Proleukin Revenue Decline: Slight decrease in Proleukin revenue due to inventory timing, which may affect overall revenue stability.

Competitive Landscape: Concerns regarding emerging competitors, particularly Replimune and Obsidian, although management believes Iovance's established infrastructure and experience provide a competitive moat.

Regulatory Risks: Ongoing regulatory processes for new indications and international markets may present uncertainties.

5Notable Q&A Insights

Demand Drivers: Management emphasized that the revenue increase was driven by organic demand rather than one-time factors, with a significant rise in physician awareness and clinical evidence supporting Amtagvi.

LUN-202 Trial Update: Enrollment is nearly complete, with expectations to release data before all patients are evaluable, focusing on maintaining trial integrity.

Community vs. Academic ATCs: Community ATCs are showing strong growth and earlier patient referrals, which may enhance overall treatment volume.

Protocol Amendments: A protocol amendment for the endometrial study aims to focus on specific patient subtypes, enhancing the precision of TIL therapy delivery. Overall, Iovance's Q2 2026 results reflect strong commercial performance and strategic advancements, positioning the company for continued growth despite competitive pressures and regulatory challenges.